Growth Hormone Pen Sourcing: 2026 Practice Buyer’s Guide

Sourcing a growth hormone pen has one of the most demanding procurement profiles in the U.S. pharmacy landscape. Every prescription requires a cold chain (2–8 °C from manufacturer to patient refrigerator), a specialty pharmacy channel, and prior authorization that often takes weeks to clear. The device choice itself locks the patient in for years: Norditropin FlexPro, Genotropin Pen, Omnitrope Pen, Saizen click.easy, Zomacton with ZomaJet, or one of the three newer once-weekly long-acting products — Skytrofa, Sogroya, or Ngenla.

Two changes in 2025–2026 have made this already-complex landscape harder. Novo Nordisk discontinued the Norditropin 30 mg/3 mL presentation in late 2025, removing a workhorse SKU from the supply chain. And the three long-acting once-weekly products (Skytrofa, Sogroya, Ngenla) have moved from new-launch territory into formulary contention, with several payers naming long-acting agents as preferred in 2026 plan updates. Meanwhile the prior-authorization bottleneck that has slowed growth hormone access for years has, if anything, intensified — a 2024 NPR investigation tied the worsening of the somatropin shortage directly to PA delays at the payer level.

This guide walks pediatric endocrinology practices, adult endocrinology practices, specialty pharmacies, and hospital outpatient pharmacies through the current growth hormone supply landscape: every approved brand and device, the long-acting transition, cold chain handling, par levels by facility type, and the procurement workflow that keeps patients on therapy without interruption.

Why Growth Hormone Procurement Is Uniquely Complex

Most prescription pharmaceuticals can be ordered, stored, and dispensed through routine pharmacy workflows. Recombinant human growth hormone (rhGH) requires four parallel workflows that must align before the first dose reaches the patient.

Cold chain. Every somatropin product — daily-injection or once-weekly — must be stored and shipped at 2–8 °C. Excursions outside that range affect product stability and clinical efficacy. The procurement chain has to verify temperature monitoring at every handoff between manufacturer, distributor, specialty pharmacy, and patient.

Brand-only landscape. Unlike most pharmaceutical categories, there are no traditional small-molecule generics for growth hormone. Omnitrope is FDA-approved as a biosimilar (the first U.S. biosimilar somatropin), but the rest of the rhGH market is brand-name. Multi-manufacturer sourcing for growth hormone means choosing between brand products, not switching to a generic.

Specialty pharmacy distribution. Growth hormone is typically dispensed through specialty pharmacy channels (Accredo, CVS Specialty, OptumRx Specialty, Cigna Specialty, and manufacturer-affiliated programs such as NovoCare and the Pfizer Patient Assistance Program). A practice that prescribes growth hormone is rarely the same entity that physically dispenses it.

Prior authorization gating. Almost every commercial and Medicare payer requires prior authorization before covering growth hormone. PA criteria vary by payer and by indication (pediatric GHD, adult GHD, Turner syndrome, Prader-Willi, idiopathic short stature, SGA, CKD, SHOX deficiency, Noonan syndrome, HIV-associated wasting). PA denials and step-edit requirements drive much of the patient access delay procurement teams have to plan around.

A pharmacy or practice that tries to handle growth hormone like any other Rx will under-staff for PA work, under-budget for cold chain handling, and under-stock for the patient mix actually walking through the door.

The Growth Hormone Product Landscape in 2026

The U.S. somatropin landscape includes several FDA-approved brand products across daily-injection and once-weekly long-acting categories, each with distinct indications, device characteristics, and procurement considerations. The products below are the most-prescribed; Serostim (somatropin for HIV-associated wasting) and a small number of restricted-distribution products are covered in the regulatory section.

Daily-injection somatropin products

• Norditropin (Novo Nordisk): FlexPro prefilled, multi-dose pen, color-coded by strength. Pediatric GHD, adult GHD, Turner, SGA, ISS, Noonan, SHOX.
• Genotropin (Pfizer): Genotropin Pen 5, Pen 12, and MiniQuick single-dose device. Pediatric GHD, adult GHD, Turner, Prader-Willi, ISS, SGA, SHOX.
• Omnitrope (Sandoz): Pen 5, Pen 10, cartridges, and vials. Same indications as reference somatropin (FDA-approved biosimilar).
• Saizen (EMD Serono): click.easy reconstitution device and EasyPod auto-injector with usage tracking. Pediatric GHD, adult GHD.
• Zomacton (Ferring): Vials with the ZomaJet 2 Vision needle-free device or standard needle. Pediatric GHD, Turner, SHOX, ISS.

Once-weekly long-acting growth hormone products

• Skytrofa (lonapegsomatropin, Ascendis Pharma): Pediatric GHD (≥1 year), with subsequent pediatric label considerations.
• Sogroya (somapacitan, Novo Nordisk): Adult GHD; pediatric GHD (≥2.5 yrs, approved 2023); 2026 label expansion added SGA, Noonan syndrome, and idiopathic short stature.
• Ngenla (somatrogon, Pfizer / OPKO): Pediatric GHD.

The long-acting transition is the biggest structural change in growth hormone procurement in the last decade. Once-weekly products shift the injection burden from 6–7 injections per week to 1 per week, materially improving patient adherence and changing refill-volume calculations for procurement teams. Several payer formularies have begun naming Sogroya and Skytrofa as preferred long-acting options, with Ngenla covered case-by-case — verify against each plan’s current formulary.

The 2025–2026 Somatropin Supply Picture

Two supply events are shaping growth hormone procurement this year.

The Norditropin 30 mg/3 mL discontinuation. Novo Nordisk discontinued the Norditropin 30 mg/3 mL FlexPro presentation in late 2025. This was a high-volume SKU for adult GHD patients on higher doses, and its discontinuation has shifted demand to the 15 mg/1.5 mL and 10 mg/1.5 mL presentations. Practices that historically stocked the 30 mg pen for adult patients need to convert those prescriptions to two 15 mg pens — which doubles cold chain volume and changes refill cadence.

The broader somatropin supply picture. ASHP and FDA shortage reporting through 2024 and 2025 listed somatropin injection on the active drug shortages page at various points, with availability shifting between Novo Nordisk (Norditropin), Pfizer (Genotropin), and Sandoz (Omnitrope) depending on lot-release timing. The underlying issue has not been a single manufacturing failure but a demand–supply imbalance compounded by prior-authorization delays. Our injectable drug shortage guide covers the broader 2026 shortage context that growth hormone procurement sits inside.

The 2024 NPR investigation made the structural point explicitly: prior-authorization delays at the payer level shift demand in ways manufacturers cannot easily predict. When PA approvals cluster at quarter-end, manufacturer demand spikes; when payers tighten step-edits, demand drops. The procurement implication is that no single manufacturer’s supply outlook is reliable in isolation — facilities serving growth hormone patients need working relationships with at least two, and ideally three, of the major manufacturers.

Prior Authorization — The Real Procurement Bottleneck

Procurement teams sometimes treat prior authorization as a clinical workflow problem rather than a supply chain problem. For growth hormone, it is both.

PA criteria vary by payer but typically require:

• Diagnosis documentation (IGF-1 levels, stimulation testing results, bone age X-rays for pediatric)
• Height percentile and growth velocity data over time
• Failed alternative therapies where relevant
• Step-edit through a preferred product before access to non-preferred
• Specialty pharmacy enrollment confirmation
• Periodic re-authorization (typically annual, sometimes more frequent)

The procurement-side framework that works:

• Standardize the PA submission packet. Build a single documentation template that satisfies the most-restrictive payer in your mix — most other payers will accept it.
• Track PA status in the prescribing record, not just the pharmacy record. Procurement teams need visibility into pending PAs so refill timing matches approval timing.
• Coordinate with specialty pharmacy. Accredo, CVS Specialty, OptumRx Specialty, and the manufacturer programs (NovoCare, Pfizer PAP, Sandoz One Source, EMD Serono OneSource, Ferring HCP Resource) each have different turn-times and documentation requirements.
• Use manufacturer patient-assistance programs. Novo Nordisk’s NovoCare, Pfizer RxPathways and product-specific copay programs, Sandoz One Source, and similar programs from EMD Serono and Ferring can bridge patients during PA processing or coverage gaps. Know the enrollment workflow for each before you need it — exact program names vary by manufacturer and may update annually.

A useful quarterly audit metric is average PA-to-fulfillment time per payer and per product, with the bottleneck identified — diagnostic documentation, payer turn-time, specialty pharmacy enrollment, or step-edit hierarchy. That answer changes by payer and quarter, and it informs which products and which manufacturers to keep first-line.

Cold Chain Logistics and Storage

Every somatropin product is a temperature-controlled biologic.

• Manufacturer to wholesaler: 2–8 °C continuous. Validated shipper with temperature monitoring.
• Wholesaler to specialty pharmacy / practice: 2–8 °C continuous. Validated shipper, signature required, temperature data reviewed on receipt.
• Practice or specialty pharmacy storage: 2–8 °C in a monitored refrigerator. Continuous temperature logging, alarmed system, backup power.
• Patient transport home: 2–8 °C in an insulated cooler with ice packs. Patient education on transport is critical.
• Patient home storage: 2–8 °C in a refrigerator (some products tolerate brief excursions during use). Patient education on storage.
• In-use stability: Product-specific (typically 14–28 days at 2–8 °C; some allow brief room-temperature periods). Reference each product’s labeling.

Practices that dispense growth hormone in-office (less common, but real for some pediatric endo practices and specialty pharmacies) need a dedicated pharmaceutical-grade refrigerator with:

• Continuous temperature monitoring with alarming for excursions
• Battery or generator backup power
• Documentation of monthly verification per state pharmacy board requirements
• A standard operating procedure for temperature excursions (quarantine, manufacturer consultation, lot disposition)

The procurement question for any growth hormone shipment is: “What was the temperature profile during transit, and is the data accessible to verify before I accept the shipment?” A distributor that cannot answer that affirmatively is not equipped for biologic distribution.

Specialty Pharmacy Channels and Distribution

Growth hormone is one of the categories where the distribution chain is intentionally narrow. The major specialty pharmacy networks that dispense rhGH in the U.S. include:

• Accredo (Cigna / Express Scripts) — large network, broad payer coverage
• CVS Specialty — integrated with CVS Caremark PBM
• OptumRx Specialty — integrated with UnitedHealthcare Optum
• Walgreens Specialty Pharmacy — broad payer coverage

Manufacturer-aligned programs:

• NovoCare (Novo Nordisk — Norditropin, Sogroya)
• Pfizer Specialty Pharmacy / Pfizer Patient Assistance Program (Genotropin, Ngenla)
• Sandoz One Source (Omnitrope)
• EMD Serono OneSource (Saizen)
• Ferring HCP Resource (Zomacton)
• Ascendis Pharma patient support program (Skytrofa — verify current program name with the manufacturer)

For practices that prescribe but don’t dispense, the workflow is to send the prescription to the patient’s assigned specialty pharmacy (determined by their insurance) and coordinate enrollment, training, and refill timing.

For specialty pharmacies that dispense directly, the workflow is to maintain manufacturer relationships for each brand carried and stock multi-product inventory so payer-required substitutions happen without patient disruption.

For hospital outpatient pharmacies serving endocrinology referrals, the workflow is hybrid — discharge-bridging supply on-site, with steady-state refills through specialty pharmacy channels.

Par Levels by Practice Type

Growth hormone par levels are intensely specific to patient panel. The frameworks below are starting points.

Pediatric endocrinology specialty practice (in-office dispensing or sample stock)

• Representative samples for each major product on formulary (Norditropin, Genotropin, Omnitrope, Skytrofa, Sogroya, Ngenla) so providers can demonstrate device handling to families during training visits
• Daily-injection products at 14-day patient-bridge supply for new starts pending specialty pharmacy delivery
• Once-weekly products at 4-week patient-bridge supply (one box covers the bridge period)
• Refrigerator capacity audit: a busy pediatric endo practice can fill a dedicated refrigerator quickly

Adult endocrinology specialty practice

• Lighter on-site stock — most adult patients go directly to specialty pharmacy dispensing
• Maintain sample devices for patient training only
• Coordinate manufacturer-program enrollment with the specialty pharmacy on each new prescription

Specialty pharmacy

• Multi-product inventory across daily-injection and once-weekly somatropin products
• Cold chain capacity sized to peak monthly fill volume + 30% buffer
• Multi-manufacturer relationships (Novo Nordisk, Pfizer, Sandoz at minimum; EMD Serono, Ferring, Ascendis depending on payer mix)
• 14-day reorder trigger from each manufacturer

Hospital outpatient pharmacy

• Discharge-bridging supply for newly diagnosed pediatric and adult GHD patients
• One or two preferred products at 14-day patient-bridge par
• Documented specialty pharmacy referral pathway for steady-state refills

Concierge or boutique endocrinology practice

• Patient-specific stock pattern based on existing panel
• Cold chain handling appropriate to the smaller volume
• Streamlined manufacturer-program enrollment workflow for the limited patient list

DSCSA, REMS, and Regulatory Considerations

Growth hormone products are DSCSA-regulated, which means lot-level chain of custody must be tracked through the entire distribution chain.

• Distributor must hold active state wholesale pharmaceutical distribution licenses in your state and every state where patients receive shipments — verify the public license listing before any rhGH order
• DSCSA transaction documentation (transaction information and transaction statement) required for every shipment, with interoperable electronic tracing per the enhanced requirements
• Cold chain temperature data must accompany each lot through every handoff

Some products and indications carry additional regulatory considerations:

• Serostim (somatropin for HIV-associated wasting) has historically been subject to anti-diversion / restricted-distribution controls — confirm current REMS or restricted-distribution requirements before sourcing.
• Federal law (21 U.S.C. § 333(e)) restricts the distribution and possession of human growth hormone for any use other than FDA-authorized indications pursuant to a physician’s order — and the FDA reads “distribution” to include writing the prescription, with the DEA authorized to investigate. Ensure prescriptions align with FDA-approved indications and that documentation of medical necessity is maintained.

The practical point: growth hormone is one of the categories where a non-DSCSA-compliant or non-state-licensed distributor is both legally problematic and clinically risky. Verify your distributor’s standing before placing any growth hormone order.

How USA MedPremium Approaches Growth Hormone Procurement

Growth hormone is one of the categories where USA MedPremium’s specialty-pharmaceutical procurement framework matters most. Our 2026 approach includes:

• Active DSCSA-compliant chain of custody on every shipment, with cold chain temperature data accessible per lot
• State wholesale pharmaceutical distribution licenses published for verification
• Multi-manufacturer sourcing across Novo Nordisk, Pfizer, Sandoz, EMD Serono, Ferring, and Ascendis Pharma where availability permits
• Validated cold-chain shippers for every growth hormone order
• Procurement specialists available 24/7 to coordinate with specialty pharmacy partners, manufacturer assistance programs, and prior-authorization workflows
• Bridge-supply coordination for newly diagnosed patients pending specialty pharmacy delivery

Explore the catalog directly:

• Pharmacy category
• Rx prescriptions category
• Needles and syringes
• Pharmacy supplies
• Vaccines

Related reading:

• Hormone Replacement Therapy Supply Guide: Patches, Injectables, and What Facilities Need to Know About HRT Procurement
• Cardiovascular Medications Sourcing Guide: A 2026 Facility Buyer’s Playbook

Sources & References

• FDA — Drug Shortages (somatropin listings)
• ASHP — Current Drug Shortages (somatropin injection detail)
• NPR — Prior authorizations make growth hormone shortage worse (Apr 2024)
• Pediatric Endocrine Society — Sogroya (somapacitan) clinical overview
• Federal law — 21 U.S.C. § 333(e), restrictions on distribution and possession of human growth hormone